Wells Fargo initiated coverage of Guardant Health (GH) with an Overweight rating and $72 price target The firm is positive on the company’s oncology-focused portfolio with “multiple patient touchpoints.” Guardant’s new products and expanded indications bring an acceleration in revenue growth over the next two years, the analyst tells investors in a research note. Wells sees 30% annual growth through 2028, well above the rate of peers.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Expands Board, Appoints Alex Azar
- Guardant Health reaches strategic pact with LabFlorida/SunDx Labs
- Guardant Health: Buy Rating Maintained Despite Disappointing Shield V2 Data, Strong Market Position Justifies Optimism
- Guardant Health price target raised to $70 from $65 at BTIG, remains Top Pick
- Guardant Health: Strong Market Position and Optimistic Outlook with Raised Price Target